Vaxxinity, Inc. (VAXX): Price and Financial Metrics
VAXX Price/Volume Stats
Current price | $0.72 | 52-week high | $3.10 |
Prev. close | $0.69 | 52-week low | $0.56 |
Day low | $0.67 | Volume | 338,451 |
Day high | $0.73 | Avg. volume | 411,807 |
50-day MA | $0.71 | Dividend yield | N/A |
200-day MA | $1.36 | Market Cap | 90.94M |
VAXX Stock Price Chart Interactive Chart >
Vaxxinity, Inc. (VAXX) Company Bio
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
Latest VAXX News From Around the Web
Below are the latest news stories about VAXXINITY INC that investors may wish to consider to help them evaluate VAXX as an investment opportunity.
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityBiogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog. |
FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug successBreakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis. |
Vaxxinity to Present at Upcoming November Medical and Investor ConferencesCAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November. Vaccines Summit – 2023Date: Tuesday, November 14, 2023 Time: 12:20 – 12:40 p.m. (ET)Title: UB-612: A novel peptide/protein subunit COVID-19 vaccine booster stimulated broadly neutralizi |
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateCAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies worldwide. This quarter, we have |
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declineKey Insights The considerable ownership by private companies in Vaxxinity indicates that they collectively have a... |
VAXX Price Returns
1-mo | -7.07% |
3-mo | -15.29% |
6-mo | -47.45% |
1-year | -67.20% |
3-year | N/A |
5-year | N/A |
YTD | -15.29% |
2023 | -39.29% |
2022 | -75.04% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...